• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    RedChip CEO Dave Gentry Invited to Join Forbes Business Council

    1/25/23 8:00:00 AM ET
    $AREC
    $BIVI
    $GNS
    $RVPH
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AREC alert in real time by email

    ORLANDO, FL / ACCESSWIRE / January 25, 2023 / RedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council.

    The Forbes Business Council committee invited Gentry to join the elite group of business leaders in recognition of his passion for helping entrepreneurs achieve success. The invitation-only community is made up of successful business owners and executives who have been chosen based on their accomplishments and experience.

    As a member, Gentry will be able to leverage the Forbes Business Council's collective resources to help foster growth in the RedChip Companies community. He will also be able to participate in exclusive events, such as invite-only webinars and podcasts, publish expert insights as a contributing writer on the Forbes platform, access a private community of members, and more.

    Gentry commented, "I look forward to sharing insights gained from my decades of experience working with executives in the small-cap markets. I believe this is a great opportunity to enhance my contributions to the entrepreneurial spirit that drives business innovations globally, while also gaining valuable new insights from industry veterans."

    Gentry is the author of Small Stocks, Big Money, a Wiley-published book of interviews with the world's most successful small-cap investors. He has been a consultant to more than 1,000 public companies and assisted dozens of public companies in the up-listing and capital-raising process. In 2012 he founded The RedChip Money Report™, a weekly cable TV financial news show broadcast in 177 million homes. He has appeared on CNBC and Fox Business News and is widely known as a thought leader in the small-cap space.

    Gentry has been a presenter at the New York Society of Security Analysts, Deal Flow Media conferences, and other small-cap conferences, and he has rung the NASDAQ bell on three occasions. In 2011, he was honored by Inc. Magazine as CEO of one of the fastest-growing private companies in America. In 1996, he won the Republican nomination in the 5th District of Florida for the United States House of Representatives. In 1994 he co-founded the First Amendment Coalition, an independent, nonprofit, collegiate-based student organization, and received national and international attention for his work defending free speech on college campuses. Gentry's activism led to his book 100+ Cases of Campus Censorship, published by David Horowitz's Second Thoughts Books. Gentry earned his Master of Education from the University of Florida in 1993.

    RedChip currently represents more than 70 clients, including some of the best emerging growth companies in the small-cap space, such as Genius Group (NYSE:GNS), Reviva Pharmaceuticals (NASDAQ:RVPH), Zomedica (NYSE:ZOM), BioVie (NASDAQ:BIVI), and American Resources Corporation (NASDAQ:AREC).

    About Forbes Business Council

    The Forbes Business Council is an exclusive platform that brings together successful business owners and executives from all over the world. Members are handpicked by the Forbes Business Council committee based on their accomplishments, experience, and commitment to helping entrepreneurs reach their goals.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Matt Sheldon
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/736680/RedChip-CEO-Dave-Gentry-Invited-to-Join-Forbes-Business-Council

    Get the next $AREC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AREC
    $BIVI
    $GNS
    $RVPH

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    American Resources Corporation
    $AREC
    9/15/2025$6.00Buy
    D. Boral Capital
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/20/2023$12.00Buy
    ROTH MKM
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    Zomedica Corp.
    $ZOM
    1/6/2023$6.00Buy
    Dawson James
    BioVie Inc.
    $BIVI
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    BioVie Inc.
    $BIVI
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $AREC
    $BIVI
    $GNS
    $RVPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genius Group appoints Robert Kiyosaki as Board Advisor

    SINGAPORE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that it has appointed Robert Kiyosaki as an advisor to the Board. Mr. Kiyosaki is the author of 29 books including ‘Rich Dad, Poor Dad' - the #1 personal finance book of all time. ‘Rich Dad Poor Dad' is the longest running bestseller on all four lists that report to Publisher's Weekly: The New York Times, Business Week, The Wall Street Journal and USA Today. It also held a top spot on the New York Times list for over five years running. The book has been translated into 45 languages and is available in 90 coun

    9/30/25 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    BioVie to Host Live Investor Webinar and Q&A on Oct. 8

    CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, president and CEO of BioVie, who will discuss bezisterim (NE3107), the company's first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer's, Parkinson's, and long COVID. Clinical studies have shown encouraging signals of improved cognition, motor function and

    9/26/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diamond Equity Research Releases Update Note on Genius Group Ltd. (NYSE: GNS)

    New York, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released update note on Genius Group Ltd. (NYSE: GNS). The update note includes information on the Genius Group Ltd.' financial results, management commentary, recent developments, outlook, risks, and our revised valuation estimates. The research summary below is from a report commissioned by Genius Group Ltd. and produced by Diamond Equity Research. Investors can find various risk factors in the update report and in the respective financial filings for Genius Group Limited. The update note is available below. Genius Group Update

    9/25/25 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AREC
    $BIVI
    $GNS
    $RVPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 12,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/20/25 12:33:35 PM ET
    $AREC
    Coal Mining
    Energy

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 13,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/1/25 1:26:00 PM ET
    $AREC
    Coal Mining
    Energy

    $AREC
    $BIVI
    $GNS
    $RVPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 12,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/20/25 12:33:35 PM ET
    $AREC
    Coal Mining
    Energy

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 13,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/1/25 1:26:00 PM ET
    $AREC
    Coal Mining
    Energy

    $AREC
    $BIVI
    $GNS
    $RVPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Reviva Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $2.00

    9/29/25 9:59:06 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital resumed coverage on American Resources Corp. with a new price target

    D. Boral Capital resumed coverage of American Resources Corp. with a rating of Buy and set a new price target of $6.00

    9/15/25 8:07:21 AM ET
    $AREC
    Coal Mining
    Energy

    ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

    ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    9/20/23 7:22:47 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    SEC Filings

    View All

    SEC Form 6-K filed by Genius Group Limited

    6-K - Genius Group Ltd (0001847806) (Filer)

    9/30/25 8:53:51 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.

    SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    9/29/25 6:59:03 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

    9/26/25 5:10:14 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Leadership Updates

    Live Leadership Updates

    View All

    Genius Group appoints Robert Kiyosaki as Board Advisor

    SINGAPORE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that it has appointed Robert Kiyosaki as an advisor to the Board. Mr. Kiyosaki is the author of 29 books including ‘Rich Dad, Poor Dad' - the #1 personal finance book of all time. ‘Rich Dad Poor Dad' is the longest running bestseller on all four lists that report to Publisher's Weekly: The New York Times, Business Week, The Wall Street Journal and USA Today. It also held a top spot on the New York Times list for over five years running. The book has been translated into 45 languages and is available in 90 coun

    9/30/25 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Genius Group Board appoints Kevin Malone as Board Advisor.

    SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that it has appointed Kevin Malone as an advisor to the Board. Mr. Malone brings experience advising companies and investors on fighting market manipulation, together with over 40 years of family experience in wealth management Kevin Malone is the CEO and President of Malone Wealth, a Registered Investment Advisory Firm, managing a range of investments in companies focused at AI, Web3 and exponential technology. He also founded the Malone Wealth Charitable Fund with a mission to empower the next generation with

    6/30/25 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

    The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

    5/5/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Financials

    Live finance-specific insights

    View All

    Diamond Equity Research Releases Update Note on Genius Group Ltd. (NYSE: GNS)

    New York, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released update note on Genius Group Ltd. (NYSE: GNS). The update note includes information on the Genius Group Ltd.' financial results, management commentary, recent developments, outlook, risks, and our revised valuation estimates. The research summary below is from a report commissioned by Genius Group Ltd. and produced by Diamond Equity Research. Investors can find various risk factors in the update report and in the respective financial filings for Genius Group Limited. The update note is available below. Genius Group Update

    9/25/25 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Genius Group Announces 25% Increase in Revenue on proforma basis, 57% Decrease in Net Loss per Share in First Half of 2025

    Total assets increased 20% to $121.3 million SINGAPORE, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced its financial results for the first half of 2025. Roger Hamilton, CEO of Genius Group, said "In the first half of 2025, Genius Group was hamstrung by a preliminary injunction preventing the company from raising funds or building its treasury. We have claimed in a RICO lawsuit (Case No: 1:25-cv-21496-BB) that this was a deliberate act taken by third parties to damage the company and its shareholders. We are pleased that further to the injunction being stayed on appe

    9/23/25 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

    CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.   Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United St

    8/13/25 4:05:00 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Genius Group Limited

    SC 13G - Genius Group Ltd (0001847806) (Subject)

    11/14/24 5:32:28 PM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 5:16:56 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 4:15:57 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care